Abstract:Lamin A/C gene ( LMNA ) mutations contribute to severe striated muscle laminopathies, affecting cardiac and skeletal muscles, with limited treatment options. In this study, we delve into the investigations of five distinct LMNA mutations, including three novel variants and two pathogenic variants identified in patients with muscular laminopathy. Our approach employs zebrafish models to comprehensively study these variants. Transgenic zebrafish expressing wild-type LMNA and each mutation undergo extensive morphological profiling, swimming behavior assessments, muscle endurance evaluations, heartbeat measurement, and histopathological analysis of skeletal muscles. Additionally, these models serve as platform for focused drug screening. We explore the transcriptomic landscape through qPCR and RNAseq to unveil altered gene expression profiles in muscle tissues. Larvae of LMNA (L35P), LMNA (E358K), and LMNA (R453W) transgenic fish exhibit reduced swim speed compared to LMNA (WT) measured by DanioVision. All LMNA transgenic adult fish exhibit reduced swim speed compared to LMNA (WT) in T-maze. Moreover, all LMNA transgenic adult fish, except LMNA (E358K), display weaker muscle endurance than LMNA (WT) measured by swimming tunnel. Histochemical staining reveals decreased fiber size in all LMNA mutations transgenic fish, excluding LMNA (WT) fish. Interestingly, LMNA (A539V) and LMNA (E358K) exhibited elevated heartbeats. We recognize potential limitations with transgene overexpression and conducted association calculations to explore its effects on zebrafish phenotypes. Our results suggest lamin A/C overexpression may not directly impact mutant phenotypes, such as impaired swim speed, increased heart rates, or decreased muscle fiber diameter. Utilizing LMNA zebrafish models for drug screening, we identify l -carnitine treatment rescuing muscle endurance in LMNA (L35P) and creatine treatment reversing muscle endurance in LMNA (R453W) zebrafish models. Creatine activates AMPK and mTOR pathways, improving muscle endurance and swim speed in LMNA (R453W) fish. Transcriptomic profiling reveals upstream regulators and affected genes contributing to motor dysfunction, cardiac anomalies, and ion flux dysregulation in LMNA mutant transgenic fish. These findings faithfully mimic clinical manifestations of muscular laminopathies, including dysmorphism, early mortality, decreased fiber size, and muscle dysfunction in zebrafish. Furthermore, our drug screening results suggest l -carnitine and creatine treatments as potential rescuers of muscle endurance in LMNA (L35P) and LMNA (R453W) zebrafish models. Our study offers valuable insights into the future development of potential treatments for LMNA -related muscular laminopathy.

Suppression of myopathic lamin mutations by muscle-specific activation of AMPK and modulation of downstream signaling

In Silico and In Vivo Analysis of Amino Acid Substitutions That Cause Laminopathies

LMNA-related Muscular Dystrophy Involving Myoblast Proliferation and Apoptosis Through the FOXO1/GADD45A Pathway.

Eliminating elevated p53 signaling fails to rescue skeletal muscle defects or extend survival in lamin A/C-deficient mice

SMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophy

Creatine and l-carnitine attenuate muscular laminopathy in the LMNA mutation transgenic zebrafish

A new laminopathy caused by an Arg133/Leu mutation in lamin A/C and the effects thereof on adipocyte differentiation and the transcriptome.

Increasing autophagy and blocking Nrf2 suppress laminopathy-induced age-dependent cardiac dysfunction and shortened lifespan

Genetic and Pathophysiological Basis of Cardiac and Skeletal Muscle Laminopathies

Human laminin-111 and laminin-211 protein therapy prevents muscle disease progression in an immunodeficient mouse model of LAMA2-CMD

Nerve Pathology is Prevented by Linker Proteins in Mouse Models for LAMA2-related Muscular Dystrophy.

Ryanodine receptor remodeling in cardiomyopathy and muscular dystrophy caused by lamin A/C gene mutation

A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene

A lamin A/C variant causing striated muscle disease provides insights into filament organization

The zebrafish candyfloss mutant implicates extracellular matrix adhesion failure in laminin alpha2-deficient congenital muscular dystrophy

Nuclear Envelope Dystrophies Show a Transcriptional Fingerprint Suggesting Disruption of Rb-MyoD Pathways in Muscle Regeneration.

Nuclear Factor-κB Pathway Mediates the Molecular Pathogenesis of LMNA -Related Muscular Dystrophies

Global Proteomic Analysis Reveals Alterations in Differentially Expressed Proteins between Cardiopathic Lamin A/C Mutations

The zebrafish candyfloss mutant implicates extracellular matrix adhesion failure in laminin α2-deficient congenital muscular dystrophy

A Novel Mouse Model for LAMA2-Related Muscular Dystrophy: Analysis of Molecular Pathogenesis and Clinical Phenotype